Vaginal Antimicrobacterial Preparation Before Cesarean Secation for Endometritis Prevention
Launched by RAMBAM HEALTH CARE CAMPUS · Mar 22, 2017
Trial Information
Current as of July 04, 2025
Unknown status
Keywords
ClinConnect Summary
BACKGROUND In the last decades, caesarean sections rate have escalated steadily worldwide. In 2013, more than 32.7% births in the United States were by cesarean section 1. These high rates of cesarean deliveries are of substantial concern due to the potential associated complications such as endometritis (6-11%) 2, wound complications (1-2%) 2, hemorrhage, injury to pelvic organs (0.2-0.5%)2, and thromboembolic disorders (100-240 per100,000) 3 .
One of the common complications following CS is endometritis. Post cs endometritis prolongs the patient hospitalization therefore not only elevati...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • an elective or emergent CS in a woman who did not report having a fever or skin infection signs in the 5 days prior to surgery.
- Exclusion Criteria:
- • 1. a known allergy to antiseptic soap, chlorohexidine-alcohol or shellfish
- • 2. women who had any infection in the perioperative period.
About Rambam Health Care Campus
Rambam Health Care Campus is a leading medical institution located in Haifa, Israel, renowned for its comprehensive patient care, advanced research initiatives, and commitment to medical education. As a prominent clinical trial sponsor, Rambam is dedicated to advancing healthcare through innovative research and development, facilitating a wide range of clinical studies across various therapeutic areas. The campus boasts state-of-the-art facilities, a multidisciplinary team of expert researchers and clinicians, and a robust infrastructure that supports rigorous scientific inquiry and ethical standards in clinical trials. By fostering collaboration and leveraging cutting-edge technology, Rambam Health Care Campus aims to enhance treatment options and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials